Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
Kisspeptin vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
- Neither record represents a broadly FDA-approved treatment.
⇄ Different
Biggest Difference
Kisspeptin is distinguished by an upstream reproductive neuropeptide family rather than an approved hormone replacement or fertility drug. Human studies used specific kisspeptin-54 or kisspeptin-10 formulations under tightly monitored research conditions; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
Kisspeptin is distinguished in the current record by an upstream reproductive neuropeptide family rather than an approved hormone replacement or fertility drug. Human studies used specific kisspeptin-54 or kisspeptin-10 formulations under tightly monitored research conditions. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceCagrilintide
Kisspeptin: Early human evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
Kisspeptin: Investigational. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthCagrilintide
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
Kisspeptin
- Oocyte maturation during monitored IVF
- Hypothalamic amenorrhea
- LH and FSH release
- Endogenous testosterone physiology
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
KisspeptinInvestigational
Investigational. No FDA-approved kisspeptin drug product was located through July 25, 2026.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
KisspeptinPhase 2 + small controlled studies
Two IVF oocyte-maturation studies plus multiple small randomized or crossover human studies of LH/FSH release, hypothalamic amenorrhea, and sexual processing.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
KisspeptinNot demonstrated
No dedicated controlled weight-loss or fat-loss evidence was located. Acute reproductive-hormone signaling should not be presented as a body-composition treatment.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
KisspeptinHormone physiology only
No diabetes-efficacy evidence. A tiny proof-of-concept study in men with type 2 diabetes measured LH and testosterone—not glucose, complications, or diabetes treatment outcomes.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
KisspeptinNo dedicated evidence
No dedicated controlled obstructive-sleep-apnoea efficacy evidence was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
KisspeptinNo outcomes evidence
No cardiovascular-outcomes or cardiovascular-benefit program was located. Existing studies are too small and short to characterize uncommon or long-term risk.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
KisspeptinTrial-specific IV, SC, or intranasal
Research-specific only: human studies used intravenous kisspeptin-10 or -54, subcutaneous kisspeptin-54, and one study-specific intranasal kisspeptin-54 formulation. There is no universal route or conversion.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Comparative clinical effectiveness, long-term safety, durable fertility or symptom outcomes, optimal form and schedule, and product-specific identity and stability.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
Kisspeptin
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.